Compare Expedia Group Inc (EXPE) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Novavax Inc — how do they compare? Expedia Group Inc trades at $274 (market cap $32.42B), while Novavax Inc trades at $12.79 (market cap $1.82B). The key difference: Expedia Group Inc is far larger — about 17.8× Novavax Inc's market cap, and Expedia Group Inc pays a 0.71% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and Novavax Inc for 59 Days on average.
| EXPE | NVAX | |
|---|---|---|
Market Cap | $32.42B | $1.82B |
Volume | 1,940,671 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $12.56 |
52-Week Low | $188.51 | $6.22 |
Typical Hold Time | 47 Days | 59 Days |
Enterprise Value | $30.98B | $1.39B |
Dividend Yield | 0.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $271.44, up 4.86% today, showing strong momentum after recent earnings beats. The stock exhibits a bullish technical signal, trading near resistance at $275, with solid fundamentals including a P/E of 16.99 and robust revenue growth to $14.73B in 2025. Recent news highlights competitive threats from AI agents but also underscores Expedia's strategic partnerships and B2B booking strength.
The outlook remains positive with a consensus price target of $335.06, implying 23% upside, supported by earnings momentum and market share gains. Key risks include AI disruption in travel booking and competitive pressures. Institutional sentiment is mixed but leans bullish, with growth in operating cash flow to $3.9B in 2025 providing a solid foundation.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
